Please provide your email address to receive an email when new articles are posted on . Semaglutide and tirzepatide were the least cost-effective of four obesity drugs examined in a ...
Tirzepatide and Semaglutide Improve Weight Loss, Cardiovascular Conditions, but Deemed Too Expensive
Tirzepatide and lifestyle modification generated 48,649 life-years gained per 100,000 eligible individuals, and semaglutide and lifestyle modification generated 35,634 life-years gained per ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback